bpc-157 safety data humans Peptide BPC-157: Experimental Peptide Creates Risk

Will definitely go back to him

The most likely range of outcomes, based on how analogous FDA processes have unfolded historically, is somewhere between "some peptides moved to a more permissive category, others kept on the restricted list pending further data" and "all peptides kept on the restricted list pending further data, with specific data requests for each." A blanket lifting of all restrictions is the least likely outcome and would be an unusual departure from how the agency typically handles incomplete safety data

Fantastic struggling with unthinkable choices

24 CPPD prevalence is poorly understood and New Zealand data are not available